David Santos Biography and Net Worth

David A. Santos was appointed Executive Vice President and Chief Commercial Officer in August 2020. Mr. Santos joined Rigel from Jazz Pharmaceuticals, where he held the role of hematology/oncology business unit head, responsible for leading US Commercialization of the oncology portfolio from January 2016 to July 2020. During his tenure at Jazz, he successfully grew the business unit through three launches to eventually have four promoted products in the leukemia, transplant and lung cancer markets. Prior to joining Jazz, from January 2014 to May 2015, Mr. Santos served as Vice President of sales and marketing for Medivation (now Pfizer), responsible for commercializing Xtandi for metastatic prostate cancer, and Vice President, kinase inhibitor franchise for Onyx (now Amgen), responsible for leading sales and marketing efforts with Nexavar and Stivarga. Before his work at Onyx, Mr. Santos served for nearly 9 years in roles of increasing responsibility at Genentech, Inc., where he launched and held key commercial leadership roles on several successful brands, including Avastin, Herceptin and Tarceva. Mr. Santos also held marketing and sales roles at Lilly Oncology and Bristol-Myers Squibb, where he started his pharmaceutical sales career. He received his BS in chemistry from St. Louis University.

What is David A. Santos' net worth?: The estimated net worth of David A. Santos is at least $2.53 million as of February 4th, 2025. Santos owns 53,500 shares of Rigel Pharmaceuticals stock worth more than $2,534,830 as of December 5th. This net worth evaluation does not reflect any other assets that Santos may own. Additionally, Santos receives an annual salary of $737,180.00 as EVP at Rigel Pharmaceuticals. Learn More about David A. Santos' net worth.
How old is David A. Santos?: Santos is currently 61 years old. There are 5 older executives and no younger executives at Rigel Pharmaceuticals. The oldest executive at Rigel Pharmaceuticals is Mr. Raul R. Rodriguez, President, CEO & Director, who is 63 years old. Learn More on David A. Santos' age.
What is David A. Santos' salary?: As the EVP of Rigel Pharmaceuticals, Inc., Santos earns $737,180.00 per year. The highest earning executive at Rigel Pharmaceuticals is Mr. Raul R. Rodriguez, President, CEO & Director, who commands a salary of $1,170,000.00 per year. Learn More on David A. Santos' salary.
How do I contact David A. Santos?: The corporate mailing address for Santos and other Rigel Pharmaceuticals executives is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. Rigel Pharmaceuticals can also be reached via phone at (650) 624-1100 and via email at [email protected]. Learn More on David A. Santos' contact information.
Has David A. Santos been buying or selling shares of Rigel Pharmaceuticals?: David A. Santos has not been actively trading shares of Rigel Pharmaceuticals over the course of the past ninety days. Most recently, David A. Santos sold 2,125 shares of the business's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $20.92, for a transaction totalling $44,455.00. Following the completion of the sale, the executive vice president now directly owns 53,500 shares of the company's stock, valued at $1,119,220. Learn More on David A. Santos' trading history.
Who are Rigel Pharmaceuticals' active insiders?: Rigel Pharmaceuticals' insider roster includes Raul Rodriguez (CEO), David Santos (EVP), and Dean Schorno (CFO). Learn More on Rigel Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Rigel Pharmaceuticals?: In the last twelve months, insiders at the biotechnology company sold shares 3 times. They sold a total of 9,113 shares worth more than $190,643.96. The most recent insider tranaction occured on February, 4th when CFO Dean L Schorno sold 2,036 shares worth more than $42,593.12. Insiders at Rigel Pharmaceuticals own 9.5% of the company. Learn More about insider trades at Rigel Pharmaceuticals.
Information on this page was last updated on 2/4/2025.

David A. Santos Insider Trading History at Rigel Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/4/2025	Sell	2,125	$20.92	$44,455.00	53,500
2/2/2023	Sell	538	$16.60	$8,930.80	14,461

David A. Santos Buying and Selling Activity at Rigel Pharmaceuticals

Rigel Pharmaceuticals Company Overview

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Today's Range

Now: $47.38

$46.76

$48.50

50 Day Range

MA: $35.50

$26.83

$50.96

2 Week Range

Now: $47.38

$14.63

$52.24

Volume

395,257 shs

Average Volume

650,314 shs

Market Capitalization

$859.95 million

P/E Ratio

7.68

Dividend Yield

N/A

Beta

1.11

David Santos Biography and Net Worth

What is David A. Santos' net worth?

How old is David A. Santos?

What is David A. Santos' salary?

How do I contact David A. Santos?

Has David A. Santos been buying or selling shares of Rigel Pharmaceuticals?

Who are Rigel Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Rigel Pharmaceuticals?